Serum Institute of Life Sciences will invest an additional USD 150 million in Biocon Biologics as the partners decided to restructure the deal which was inked in 2021, Biocon said on Tuesday.
With the fresh capital infusion, Serum's total investment in Biocon Biologics will touch USD 300 million.
Biocon Biologics Limited (BBL) and Serum Institute of Life Sciences (SILS) have reached an agreement to withdraw from the original equity structure contemplated under their strategic alliance announced in September, 2021, the Bengaluru-based biotechnology firm said in a statement.
As per the new terms of the collaboration, Serum Life Sciences, a part of vaccine major Serum Institute of India, would make an additional equity investment of USD 150 million through the conversion of the USD 150 million loan provided to Biocon Pharma Ltd, a wholly-owned subsidiary of Biocon Ltd, into equity in BBL, it noted.
This investment is in addition to the USD 150 million that Serum Institute of Life Sciences had invested in Biocon Biologics in November 2022, it added.
As per the new arrangement, BBL will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio which will add to BBL's product portfolio for global markets.
Serum Institute to double its investment in Biocon's unit to $300 million
Biocon Q2 results: Net profit declines 10% to Rs 168 crore, revenue up 26%
Shreehas Tambe elevated as MD & CEO of Biocon Biologics effective Monday
Covid-19 situation in India better than elsewhere: SII CEO Adar Poonawalla
Scholarships worth Rs 75 cr misappropriated by institutes in UP: ED
Infosys launches live operations platform in collaboration with ServiceNow
Zomato, Zypp join hands to deploy 100K e-scooters for last-mile delivery
Zydus Lifesciences gets nod from USFDA for metronidazole topical cream
IndusInd Bank shares jump 2% after robust Q4 earnings, stocks climb 1.90%
Akasa Air says no significant impact of delay in Boeing 737 delivery
The new terms will serve the objectives of both the companies, as it provides SILS an aggregated equity investment in BBL amounting to USD 300 million and provides BBL additional product offerings for global markets.
Biocon shares were trading 2.95 per cent up at Rs 232.20 apiece on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)